OY LX THERAPIES
Lx Therapies, founded in 2008, is a drug discovery company focused on developing genemediated therapies for the prevention and treatment of diseases of lymphatic vasculature. The initial focus of the company is on breast cancer-related lymphoedema, a relatively common complication of breast cancer treatment for which there is currently no cure or effective treatment. Lx Therapies, based in Helsinki, has received a EUR 2 million investment from Inveni Capital, the Finnish-German life sciences venture fund and a founder of Lx Therapies.
OY LX THERAPIES
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
Helsinki, Southern Finland, Finland
Country:
Finland
Status:
Active
Total Funding:
2.63 M USD
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Delenex Therapeutics
Delenex Therapeutics is engaged in developing therapeutic antibody fragments for diseases with high unmet needs.
Médipole Garonne
Médipole Garonne Clinic, focused on orthopedic surgery and care of the athlete, has reached its phase of maturity.
Investors List
Inveni Capital
Inveni Capital investment in Venture Round - OY LX Therapies
More informations about "OY LX Therapies"
OY LX Therapies - Crunchbase Company Profile & Funding
Organization. OY LX Therapies . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. About. OY LX Therapies is focused on developing gene …See details»
OY LX Therapies - Funding, Financials, Valuation & Investors
OY LX Therapies is focused on developing gene-mediated therapies for the prevention and treatment of diseases of lymphatic vasculature. Search Crunchbase. Start Free Trial . Chrome …See details»
Laurantis Pharma - VentureRadar
Laurantis is a clinical-stage specialty pharmaceutical development company formed through the merger of two independent companies, BioCis Pharma Oy and Oy Lx Therapies Ltd in late …See details»
OY LX Therapies - Crunchbase
OY LX Therapies is focused on developing gene-mediated therapies for the prevention and treatment of diseases of lymphatic vasculature. ... Solutions. Products. Resources. Pricing. …See details»
BioCis Pharma and Lx Therapies merge | Drug Discovery News
Jul 5, 2011 Oy Lx Therapies, founded in 2008, is a drug discoverycompany focused on developing gene-mediated therapies for the prevention andtreatment of diseases of lymphatic …See details»
BioCis Pharma, Lx Therapies Combine to Create Laurantis Pharma Oy
May 26, 2011 Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, BioCis Pharma Oy and Oy Lx Therapies Ltd. More information can be found at …See details»
LYMFACTIN Trademark of Oy Lx Therapies Ltd, Herantis Pharma …
LYMFACTIN is a trademark and brand of Oy Lx Therapies Ltd, Herantis Pharma Plc, Helsinki 00290, FINLAND. This trademark was filed to EUIPO on Friday, September 11, 2009. The …See details»
Lx Therapies Oy: Drug pipelines, Patents, Clinical trials - Synapse
Jun 20, 2023 0 Patents (Medical) associated with Lx Therapies Oy. Login to view more data. Pipeline. Pipeline Snapshot as of 20 Jun 2023. No pipeline posted. Login to keep update. …See details»
BioCis Pharma and Oy Lx Therapies become Laurantis
Finland-based BioCis Pharma and Oy Lx Therapies have combined to create Laurantis Pharma, a developer of clinical-stage specialist pharmaceuticals. The new company will have a broad …See details»
Articles about Oy Lx Therapies Ltd - BioSpace
2 articles about Oy Lx Therapies Ltd. Ark Therapeutics Commences Contract Manufacture For Oy Lx Therapies Ltd VEGF-C Gene Medicine Programme. 7/1/2009. Ark Therapeutics Grants …See details»
Ark Therapeutics Grants VEGF Genes Licence to Oy Lx Therapies …
Jan 14, 2009 Best Places to Work; Employer Resources; Post Jobs; Talent Solutions; Advertise; Submit a Press ReleaseSee details»
Biolactis - VentureRadar
Laurantis Pharma Finland Privately Held Laurantis is a clinical-stage specialty pharmaceutical development company formed through the merger of two independent companies, BioCis …See details»
BioCis Pharma and Oy Lx Therapies become Laurantis
Jun 2, 2011 Finland-based BioCis Pharma and Oy Lx Therapies have combined to create Laurantis Pharma, a developer of clinical-stage specialist pharmaceuticals. The new company …See details»
BioCis Pharma and Lx Therapies Combine to Create Laurantis …
May 26, 2011 New specialty pharmaceutical company will target inflammatory diseases and cancers May 25, 2011 11:43 AM Eastern Daylight Time TURKU, Finland--(EON: Enhanced …See details»
Venture Round - OY LX Therapies - 2009-01-14 - Crunchbase
Venture Round - OY LX Therapies . Save . Summary. Overview. Edit Overview Section. Organization Name . OY LX Therapies . Announced Date Jan 14, 2009; Funding Type …See details»
BioCentury - BioCis Pharma Ltd., Lx Therapies deal
Jun 13, 2011 BioCis and Lx Therapies merged to form Laurantis Pharma Oy. The newco hired Riku Rautsola, former president and CEO of Virxsys Corp. (Gaithersburg, Md.), as president …See details»
LYMFACTIN Trademark of Oy Lx Therapies Ltd. Application …
LYMFACTIN is a trademark and brand of Oy Lx Therapies Ltd, Helsinki 00290, FINLAND. This trademark was filed to EUIPO on Monday, September 14, 2009. The LYMFACTIN is under the …See details»
BioCentury - Ark Therapeutics, Oy Lx Therapies Ltd. deal
Jan 19, 2009 Ark granted Lx Therapies an exclusive, worldwide sublicense to use VEGF-C and VEGF-D genes in vector delivery systems to treat lymphatic disease. ... This Edition. ARTICLE …See details»
Laurantis Pharma - Crunchbase Company Profile & Funding
Sep 4, 2012 Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and …See details»
Ark Commences Contract Manufacture for Lx …
Ark Commences Contract Manufacture for Lx Therapies Gene Medicine Program July 3, 2009 Ark Therapeutics Group plc announces that it has signed an agreement with the private Finnish …See details»